Table 1.

PD-L1 promotor methylation (mPD-L1, beta-values) and PD-L1 mRNA expression (normalized counts) in a clinico-pathological context. Bold numbers indicate statistically significant correlations with p-values less than 0.05.

	Patients	%	Median mPD-L1	p-value	Median PD-L1 mRNA	p-value
All patients	383	100	−0.371		4.109
Missing data (methylation/mRNA expression)	11/11	2.9/2.9
Sex
Female	168	43.9	−0.372	0.67*	4.089	0.88*
Male	206	53.8	−0.370		4.135
Unknown	9	2.3
Follow-up
Patients with follow-up: OS	364	95
Events/deaths	70	18.3
Patients with follow-up: RFS	313	82
Events/recurrences	60	15.7
Mean follow-up [mo]	24.5 [21.6–27.5]
Median follow-up [mo]	13.7
Range follow-up [mo]	0.1–142.3
Age [y]
Mean	64.4 [63.0–65.7]
Median	66
≤ 66 y	193	50.4	−0.365	0.023*	3.924	0.066*
> 66 y	181	47.3	−0.380		4.544
Unknown	9	2.3
pT category
1	10	2.6	−0.369	0.41**	3.722	0.81**
2	55	14.4	−0.389		4.358
3	250	65.3	−0.371		4.135
4	46	12	−0.354		4.043
Unknown	22	5.8
pN category
0	197	51.4	−0.381	<0.001*	4.367	0.15*
1	96	25.1	−0.357		4.022
2	66	17.2	−0.350		3.983
Unknown	24	6.3
M category
0	242	63.2	−0.375	0.002*	4.313	0.045*
1	48	12.5	−0.351		3.734
Unknown	93	24.3
Microsatellite instability
MSS	258	67.4	−0.372	0.54ε	3.837	<0.001ε
MSI-L	65	17.0	−0.358		4.136
MSI-H	55	14.4	−0.371		5.545
Intermediate	3	0.8	−0.410		3.055
Unknown	2	0.5
BRAF
Wildtype	32	8.4	−0.374	0.80*	2.918	0.025*
Mutation	3	0.8	−0.383		4.347
Unknown	348	90.9
KRAS
Wildtype	32	8.4	−0.353	0.38*	2.996	0.86*
Mutation	27	7.0	−0.357		3.261
Unknown	324	84.6
MLH1 expression by IHC
Absent	58	15.1	−0.368	0.94*	3.810	0.014*
Present	176	46.0	−0.370		4.482
Unknown	149	38.9

^*Wilcoxon–Mann–Whitney U test.

^**Kruskal–Wallis test.

IHC: immunohistochemistry; OS: overall survival; RFS: recurrence free survival.